Heat Biologics, Inc. has successfully completed the manufacture of the first GMP batch of its HS-410 investigational drug for its Phase 1/2 bladder cancer trial. HS-410 is a fully-allogeneic, live-cell cancer immunotherapy, which consists of a bladder cancer cell line that has been genetically modified using Heat’s ImPACT technology platform to secrete a wide range of bladder cancer antigens designed to activate a T-cell immune response against the cancer.   Heat Biologics’ allogenei...